Author
 |
MYERS, MICHAEL - US FDA |
|
FARRELL, D - US FDA |
|
Clover, Christina |
|
Steele, Norman |
|
Submitted to: International Immunology Congress
Publication Type: Abstract Only Publication Acceptance Date: 9/14/1995 Publication Date: N/A Citation: N/A Interpretive Summary: Technical Abstract: Castrated male pigs were fed diets supplemented with 0 (picolinic acid) or 300 parts per billion Cr+3 (chromium picolinate) from 20 kg to 90 kg body weight. They were also treated daily with an i.m. injection of 0 (excipient buffer) or 100 ug/kg body weight PST in excipient buffer from 60 kg to 90 kg body weight. At 90 kg, LPS (20 ug/kg) was administered via venous catheter and blood was collected over a 24 hour period. In animals treated with 0 PST, the blood glucose concentration decreased 2 - 4 hours post-LPS regardless of Cr+3 treatment. In PST treated animals, blood glucose was elevated 1 hour post-LPS and decreased at 6 - 8 hours. Blood insulin concentration paralleled changes in glucose concentration. Non-esterified fatty acid concentration was elevated 2 hours post-LPS in 0 PST animals, while PST-treated pigs did not achieve a similar elevation until 6 hours post-LPS. Non-esterified fatty acid concentrations remained elevated at the 24 hour sampling regardless of treatment. Plasma GOT activity was elevated6 hours post-LPS and remained elevated in 0 PST animals, whereas PST treatment prevented the rise of plasma GOT. Interleukin-6 concentration was unaffected by Cr+3 and PST treatments. Compared to control animals, both Cr+3 and PST decreased the TNF alpha response to LPS. These results suggest that PST, and to a lesser extent Cr+3, provide protection against the adverse metabolic effects of LPS-induced septic shock. TNF alpha, and not interleukin-6, is a sensitive stress indicator in swine. |
